Hanmi Pharmaceutical, a leading R&D focused Korean pharmaceutical company, expanded its use of the Medidata Cloud, the Intelligent Platform for Life Sciences, to improve clinical trial efficiency and quality of results.
By adding Edge Central Monitoring and Rave eCOA/ePRO to its current use of Rave EDC, Hanmi will gain greater insight into clinical trial performance and mobile patient data.
Failing to identify data anomalies during clinical trials can hinder a study’s progress and success. Hanmi will utilize Medidata Edge Central Monitoring to: analyze clinical trial data through machine learning, and identify errors and/or outliers; monitor and analyze risk during clinical procedures; measure overall data consistency and compare across studies, indications and disease areas.
Hanmi is currently leveraging Rave EDC to manage and ingest traditional clinical trial data. With the expansion of Medidata eCOA/ePRO, Hanmi will seamlessly store patient reported outcome (PRO) data collected on mobile devices and reduce the need for time-consuming data cleansing of paper-based PROs.
Established in 1973, Hanmi Pharmaceutical has become a Korea’s very first global pharmaceutical company through Korean R&D strategy starting from synthesis technology development continues to generic, IMD/FDC and innovative new drugs.
Medidata Solutions is a technology company that develops and markets software as a service solutions for clinical trials. These include protocol development, clinical site collaboration and management; randomization and trial supply management; capturing patient data through web forms, mobile health (mHealth) devices, laboratory reports, and imaging systems; quality monitor management; safety event capture; and monitoring and business analytics. Headquartered in New York (USA), Medidata has locations in China, Japan, Singapore, South Korea, the United Kingdom, and the United States.